TABLE II.
First-line phase iii trials incorporating anti-her2 therapy and endocrine therapy for metastatic hormone receptor–positive, her2-positive breast cancer
| Reference (study name) | Pts (n) | Treatment arms |
Median
|
Response rate (%) | |
|---|---|---|---|---|---|
| ttp or pfs (months) | os (months) | ||||
| Johnston et al., 200918 (EGF30008) | 263 | Letrozole 2.5 mg with lapatinib 1500 mg daily | 8.2 (p=0.019) | 33.3 (p=0.113) | 28 (p=0.021) |
| Letrozole 2.5 mg with placebo daily | 3.0 | 32.3 | 15 | ||
| Kaufman et al., 200919 (tandem) | 207 | Anastrozole 1 mg daily, with trastuzumab (4 mg/kg loading dose, then 2 mg/kg weekly) | 4.8 (p=0.002) | 28.5 (p=0.325) | 21 (p=0.018) |
| Anastrozole 1 mg daily | 2.4 | 23.9 | 7 | ||
| Huober et al., 201220 (electra) | 92 | Letrozole 2.5 mg daily, with trastuzumab (4 mg/kg loading dose, then 2 mg/kg weekly) | 14.1 (p=0.23) | nr | 27 (p=0.002) |
| Letrozole 2.5 mg daily | 3.3 | nr | 13 | ||
her2 = human epidermal growth factor receptor 2; Pts = patients; ttp = time to progression; pfs = progression-free survival; os = overall survival; nr = not reported.